Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282749 · ClinicalTrials.gov registry record · NA
Effectiveness of SisterTalk Hartford for Weight Loss Among African-American Women
A NA study, sponsored by UConn Health.
- Completed
- Registry status
- NA
- Development phase
- 322
- Enrollment target
NCT01282749: Completed NA study, sponsored by UConn Health.
NCT01282749 is a NA study that has completed, run by UConn Health. The registered enrollment target is 322 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282749, a NA study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 322 participants
- Enrollment target
Study Summary
The purpose of the SisterTalk Hartford study was to assess whether a theoretically- and scientifically-based, culturally acceptable weight loss program could be effectively translated into a faith-based program and subsequently delivered in the church to help African-American women lose weight.
Primary Outcome
Change in BMI
Interventions
- BEHAVIORAL SisterTalk Hartford
- BEHAVIORAL Attention control video series
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-08 |
| Phase | NA |
What the finished NCT01282749 record still lists
NCT01282749 is an interventional study that assigns participants to a tested intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which SisterTalk Hartford is the first listed.
NCT01282749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01282749 about?
NCT01282749 is a clinical study titled "Effectiveness of SisterTalk Hartford for Weight Loss Among African-American Women". The purpose of the SisterTalk Hartford study was to assess whether a theoretically- and scientifically-based, culturally acceptable weight loss program could be effectively translated into a faith-based program and subsequently delivered in the church to help African-American women lose weight.
What is the current status of trial NCT01282749?
This trial is currently completed. It is a NA study. The enrollment target is 322 participants. The study started on 2002-10. Estimated completion is 2006-08.
What interventions are being tested in trial NCT01282749?
The interventions under investigation include: SisterTalk Hartford (BEHAVIORAL), Attention control video series (BEHAVIORAL).
Who is sponsoring clinical trial NCT01282749?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01282749's enrollment target sits among peer trials
322 315th of 2000 higher than 1,686 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia